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Abstract 31 
 32 BACKGROUND: Pancreatic neuroendocrine neoplasms (PNENs) represent 10% of all 33 pancreatic tumors by prevalence. Their incidence has reportedly increased over recent 34 decades in parallel with that of pancreatic adenocarcinoma. PNENs are relatively rare and of 35 the few institutions that have published potential risk factors, findings have been 36 heterogenous. 37 AIM: To investigate the association between potential risk and protective factors for the 38 occurrence of sporadic PNENs across a European population from several institutions. 39 METHODS: A multinational European case-control study was conducted to examine the 40 association of selected environmental, family and medical exposure factors using a 41 standardized questionnaire in face-to-face interviews. A ratio of 1:3 cases to controls were sex 42 and age matched at each study site. Adjusted univariate and multivariate logistic regression 43 analysis were performed for statistically significant factors. RESULTS: In 201 cases and 603 44 controls non-recent onset diabetes (OR 2.09, CI 1.27-3.46) was associated with an increased 45 occurrence of PNENs. The prevalence of non-recent onset diabetes was higher both in cases 46 with metastatic disease (TNM stage III-IV) or advanced grade (G3) at the time of diagnosis. 47 The use of metformin in combination with insulin was also associated with a more aggressive 48 phenotype. Drinking coffee was more frequent in cases with localized disease at diagnosis. 49 CONCLUSIONS: Non-recent onset diabetes was associated with an increased occurrence of 50 PNENs and the combination of metformin and insulin was consistent with a more aggressive 51 PNEN phenotype. In contrast to previous studies, smoking, alcohol and first–degree family 52 history of cancer were not associated with PNEN occurrence. 53   54  55 
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 56  57 
Introduction 58 Pancreatic neuroendocrine neoplasms (PNENs) are a group of tumors which originate 59 from endocrine cells within the pancreas gland. PNENs have heterogeneous clinical behavior 60 owing to their hormone functional status, cellular characteristics and the extent of metastatic 61 disease. Whilst representing only 1-2% of pancreatic neoplasms by incidence (Fitzgerald, et 62 al. 2008; Yao, et al. 2008), PNENs may account for as much as 10% by prevalence (Yao et al. 63 2008). Such discrepancy is due in part to the relatively indolent clinical course of many PNENs 64 compared to pancreatic adenocarcinoma. PNENs are rare tumors but their incidence has 65 reportedly increased in recent decades, particularly that of non-functioning tumors 66 (Fitzgerald et al. 2008; Lepage, et al. 2004; Yao et al. 2008). To a lesser degree investigators 67 have also identified a modest increase in the incidence of pancreatic adenocarcinoma 68 (Fitzgerald et al. 2008).  69 The increased reported incidence of both endocrine and exocrine pancreatic tumors is 70 likely due to rising population lifespan and the wider availability of high resolution cross-71 sectional imaging (Del Chiaro, et al. 2013; Ellison, et al. 2014), but additionally raises the 72 possibility of changing exposure to factors which may alter the risk of pancreatic neoplasia. 73 There are a small number of case-control studies that have investigated potential risk 74 factors for the occurrence of PNENs (Ben, et al. 2016; Capurso, et al. 2009; Halfdanarson, et al. 75 2014; Hassan, et al. 2008b; Zhan, et al. 2013). These studies recruited participants from a 76 single institution or geographical region, and were recently summarized in a meta-analysis 77 that found personal history of diabetes mellitus and family history of cancer to be associated 78 with an increased risk of PNEN (Haugvik, et al. 2015). The association of PNENs with smoking 79 and alcohol drinking was less clear, and only heavy smoking and heavy alcohol consumption 80 
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reached statistical significance. The included studies differed in their design and population 81 definitions, with a considerable heterogeneity limiting the significance of the meta-analysis. 82 Moreover, these studies had some specific methodological limitations, such as the absence of 83 a power calculation and exposures were often recorded at the time of diagnosis or treatment, 84 rather than considering the exposure history prior to diagnosis. The latter raises the 85 possibility of a bias due to cancer symptoms (e.g. weight loss, new onset diabetes) or lifestyle 86 modifications such as changes in smoking behaviour and alcohol consumption. 87 It appears that there is overlap in risk factors, such as smoking and alcohol, for the 88 occurrence of PNENs and pancreatic adenocarcinoma, however, a number of other factors 89 that have been associated with the occurrence of pancreatic cancer have not, to our 90 knowledge, been investigated for PNENs. For example, the use of medications such as aspirin, 91 and the association with allergy and atopy that have been reported to be protective against 92 pancreatic adenocarcinoma occurrence (Gomez-Rubio, et al. 2015; Streicher, et al. 2014).  93 For these reasons, we conducted a multi-center European study aimed at assessing the 94 association between a large number of potential risk or protective factors for the 95 development of sporadic PNENs. 96 
 97 
Materials and Methods 98  99 
Study Design and population 100 A collaborative multicentre hospital based case-control study was conducted in six European 101 countries: Italy, Norway, Sweden, Slovenia, United Kingdom and Germany as part of the 102 
“Pancreas 2000” educational project (www.pancreas2000.org), upon local hospital ethical 103 committee approval. 104 
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A standardized questionnaire, including questions about demographics and potential 105 risk factors, such as family history of cancer, environmental factors, previous use of drugs and 106 other medical history features was administered to patients by a trained medical doctor. Each 107 questionnaire took ~15 minutes to be completed during a face-to-face interview, after gaining 108 participant consent. 109 The cases were prevalent sporadic PNEN patients diagnosed within 24 months from 110 the beginning of the study (January 2013) and new incident cases of sporadic PNENs 111 diagnosed from January 2013 to December 2015 that were recruited at the participating 112 centers. 113 The inclusion criterion was to have a histological or cytological diagnosis of PNEN. The 114 date of the confirmatory pathological report was accepted as the date of diagnosis. 115 Exclusion criteria were the presence of an inherited form of PNEN such as those 116 associated with multiple endocrine neoplasia-type 1 (MEN1), von Hipple-Lindau disease 117 (VHL), neurofibromatosis type 1 (NF-1), tuberous sclerosis (TSC), or an inability to 118 participate, such as dementia. 119 According to the absence or presence of a clinical syndrome due to hormonal 120 hypersecretion, cases were classified as non-functioning or functioning tumors (gastrinoma, 121 insulinoma, glucagonoma). For example the Zollinger Ellison Syndrome was clinically 122 suspected in the presence of a PNEN associated with peptic disease and its complications and 123 diarrhea, insulinomas in the presence of severe hypoglicamia with associated neurological 124 symptoms (varing from confusion to coma), glucagonoma in the presence of rash, glucose 125 intolerance and weight loss. In any case the syndrome was confirmed with a specific 126 laboratory work-up according to guidelines.(Falconi, et al. 2016; Jensen, et al. 2012)     127 
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Cases were classified according with the European Neuroendocrine Tumor Society 128 (ENETs) and the 2010 World Health Organization classifications (Falconi et al. 2016; Rindi G ; 129 Solcia E 2002). 130 Eligible controls were either individuals seen in the participating hospitals’ outpatient 131 clinic for a non-specific, non-organic gastrointestinal disorder (bloating, aspecyfic dyspeptic 132 symptoms, eructation) or visitors attending the same network of referring hospitals, matched 133 by country, sex and age (+/- 5 years). Visitors and hospital outpatients’ clinic belonged to the 134 same catchment area of cases. Specific exclusion criteria for controls were: 1) the presence of 135 any genetic syndrome associated with the occurrence of PNENs; 2) a history of active cancer 136 (diagnosed within 5 years); 3) any biological relation of a participating PNEN case in this 137 study; 4) a history of any chronic inflammatory condition (e.g. chronic obstructive pulmonary 138 disease, liver cirrhosis, inflammatory bowel disease, end stage kidney disease); 5) undergoing 139 evaluation of a possible familial cancer syndrome. Controls were included in the same country 140 and interviewed within 6 months of the inclusion of the matched corresponding case. 141  142 
Exposure definitions 143 Subjects were questioned about risk factors that were present at least 12 months before 144 diagnosis or presentation of symptoms, in order to avoid potential bias due to lifestyle 145 modifications, cancer symptoms or cancer treatments. 146 Subjects were considered ever smokers if they reported a cumulative lifetime smoking 147 history greater than 6 months or 100 cigarettes smoked. A quantification of the smoking habit 148 for cases and controls was performed considering the number of pack-years (pack-year = 149 number of packs per day x years of smoking), with 20 pack-years being the lower limit to 150 qualify a participant a heavy smoker. 151 
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A daily intake of at least 12.5 g of alcohol, equivalent to one glass of wine, one pint of 152 beer or one shot of hard liquor, for at least one year, was considered the cut-off to be a regular 153 ever alcohol drinker. Because of possible different drinking habits within different European 154 countries, the weekly alcohol amount was also sub-analyzed according to low (1-7 weekly 155 units assumption), medium (8-14 weekly units), medium-high (14-20 weekly units) and 156 
heavy alcohol consumption (≥21 weekly units). Coffee drinking was also recorded as ever 157 drinking (at least one cup per day) or heavy coffee drinking (>5 cups per day). 158 Height and weight were recorded from which body mass index (BMI) (kg/m2) was 159 calculated. A history of chronic pancreatitis, acute pancreatitis, peptic ulcer disease, biliary 160 stones and previous surgery were specifically recorded. Additionally, a diagnosis of diabetes 161 was documented and subdivided for type and onset. For cases, recent onset diabetes was 162 defined as that which was diagnosed in the 12 months prior to the PNEN diagnosis, and for 163 controls a diagnosis of diabetes 12 months prior to the date of recruitment was required. 164 Sensitivity analysis were also performed for different intervals of the onset of diabetes, 165 (respectively inferior to 1 year, between 1 and 3 years, between 3 and 5 years and above 5 166 years). Another sensitivity analysis was also conducted considering incident/prevalent cases 167 and hospitals controls/visitors controls compared to respective cases.  168 As atopy and allergy have been associated with a reduced risk of pancreatic cancer 169 (Gomez-Rubio et al. 2015), cases and controls were interrogated about a history of allergy, 170 with specific enquiry for eczema, hay fever and asthma. The use of aspirin, proton pump 171 inhibitors, metformin and insulin were recorded. Subjects were interrogated about 1st and 2nd 172 degree family history of cancer, and the total number of siblings and children was recorded. 173  174 
Statistical analysis 175 
8 
 
8 
 
An a priori power calculation was performed. We estimated sample size based on the 176 differences reported in the frequencies of exposure in cases and controls according to a 177 previous study (Capurso et al. 2009), and considering a ratio 1:3, with a statistical power 178 equal to 80% and an alpha error equal to 0.05. 179 According to Capurso and colleagues (Capurso et al. 2009) the reported prevalence in cases 180 and controls was respectively 53% vs. 32% for 1st degree family history of cancer, 10% vs. 2% 181 for diabetes and 14% vs. 3% for heavy alcohol consumption. Therefore, the sample size’s 182 estimate of cases and controls, to show true differences whether existing, were respectively 183 64 cases and 191 controls for 1st degree family history of cancer, 117 cases and 350 controls 184 for diabetes, 85 cases and 253 controls for heavy alcohol consumption. 185 We therefore estimated that a total of 200 cases and 600 controls across participating 186 centers, to be an adequate sample size to reveal differences in the prevalence of most risk 187 factors analyzed among cases and controls, where these exist. 188 Characteristics of cases and controls were compared by chi-square test for categorical 189 
variables or Student’s t test for continuous variables. Significant variables were analyzed by 190 logistic regression analysis adjusted for sex, age and enrolment center. A multivariable logistic 191 regression analysis, adjusted for sex, age and enrolment center was also performed with an 192 enter selection procedure for statistically significant risk factors. A dedicated statistical 193 software package (MedCald Mariakerke, Belgium) was used for data analysis. The 95 % 194 confidence interval (CI 95) was calculated where possible. All p-values were two-sided and a 195 p<0.05 was considered statistically significant . 196 
 197 
RESULTS 198 
Characteristics of cases and controls 199 
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A total of 201 cases and 603 sex and age matched controls were enrolled among the six 200 centers (Italy, Norway, Sweden, United Kingdom, Slovenia and Germany) as shown in table 1. 201 The mean age was 59.6 years in cases (CI 57.7-61.4) and 59.5 years in controls (CI 58.4-202 60.55), and 51% of cases and controls were male.  203 Amongst the 201 PNEN cases, 154 (76.6%) had a non-functioning tumor. Of the 47 204 functioning PNENs, 26 (55.3%) had an insulinoma, 9 (19.1%) a gastrinoma, 7 (14.9%) a 205 glucagonoma and 5 (10.6%) other functioning tumors. The majority were G1 (44.8%) or G2 206 (43.3%) PNENs, and were equally distributed among different disease stages (Table 1). Of the 207 201 PNEN cases, 80 (38%) cases were incident and 121 (62%) prevalent. Of the 603 controls, 208 422 (70%) were hospital outpatients controls and 181 (30%) visitors.  209 
 210 
Risk factors for the occurrence of PNEN 211 
 212 
Family history of cancer 213 The proportion of subjects who had a 1st degree family history of cancer was similar in cases 214 and in controls (respectively 51.1% vs. 45.3% p=0.17), while 2nd degree family history was 215 slightly more prevalent in cases ( 36.8% vs. 30.2% p=0.09). A 1st degree family history of 216 specific cancer sites was also not significantly different (Table 2). No cases or controls 217 reported a family history of neuro-endocrine tumor (NET). At multiple regression analysis 2nd 218 degree family history of any cancer was, however associated with an increased risk of PNEN 219 
(see Table 2 and 3). 220 
 221 
Body Mass Index 222 
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Mean BMI was not significantly different amongst cases and controls (26.8 kg/m2 (CI 26.0-223 27.5) and 26.4 kg/m2 (CI 26.4-26.8), p=0.10. Similarly, whilst the overall prevalence of obesity 224 was more frequent in cases than controls (25.5% vs. 18.2%) this was not significant (p=0.44).  225 At regression analysis after adjustment for matching variables, there remained no significant 226 association with obesity (OR 1.36, 95% CI 0.88-2.08, p=0.15) (Table 3). 227  228 
Cigarette smoking, alcohol intake and coffee drinking 229 The proportion of smokers (55.5% vs. 53.5%, p=0.59), heavy smokers (25.5% vs. 24.0%, 230 p=0.59), alcohol drinkers (75.6% vs. 70.8%, p=0.33), heavy alcohol drinkers (3.4% vs. 4.2%, 231 p=0.33), coffee drinkers (84.8% vs. 87.8%, p=0.24) and heavy coffee drinkers (18.8% vs. 232 19.2%, p=0.24) did not significantly differ between cases and controls (Table 2). 233 
 234 
History of diabetes mellitus 235 A history of diabetes mellitus was more prevalent in cases than in controls (18.4% vs. 12.3%, 236 p=0.03). This difference was greater on analysis of non-recent onset diabetes, defined as 237 diabetes diagnosed more than 12 months before the diagnosis of PNEN in cases, or 12 months 238 prior to the interview for controls (17.4% vs. 9.7%, p=0.004) (Table 2). After adjustment for 239 the matching variables, non-recent onset diabetes was confirmed to be consistent with the 240 occurrence of PNEN (OR 1.89, 95% CI 1.17-3.05, p=0.008). At multivariable analysis the 241 association with non-recent onset diabetes remained statistically significant (OR 2.09, 95% CI 242 1.27-3.45, p=0.003) (Table3).  At sensitivity analysis, a history of diabetes with an onset 243 between 1-3 year and between 3- 5 years, was increasingly prevalent in PNEN compared to 244 controls (respectively 3.0% vs 1.1% p=0.07 and 4% vs 0.9% p=0.004).  At univariable logistic 245 regression analysis this difference remained significant (respectively OR 2.56, 95% C.I 0.83-246 7.91 and OR 4.31, 95% C.I 1.43-12.98). For intervals of occurrence of diabetes superior to 5 247 
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years no statistically significant difference was found between cases and controls 248 (respectively 10.7% vs 7.4%, p=0.16) (Table 2). We also performed a separate analysis for 249 
“late onset diabetes” using as controls either only the 422 hospital controls or only the 181 250 visitors controls. In the first case the OR resulted to be 2.52 (95%CI 1.08-5.86; p=0.03), while 251 in the second one the OR was 1.7 (95%CI 0.95-3; p=0.07), most likely due to the lower 252 number of controls reducing the power of the analysis. 253 Neither the use of metformin (7.3% vs. 5.1%, p=0.3), nor insulin (4.1% vs. 1.6%, p=0.1), or 254 their association together (5.2% vs 3.4%, p=0.4) were statistically different between cases 255 and controls.   256 
Past medical history 257 With regards to past medical history, the prevalence of acute pancreatitis (3.5% vs. 2.4%, 258 p=0.60), peptic ulcer disease (12.3% vs. 10.6%, p=0.59), cholecystectomy (9.0% vs. 8.5%, 259 p=0.92) and gastrectomy (1.0% vs. 0.7%, p=0.99) were similar in cases and controls. None of 260 the participants reported a medical history of chronic pancreatitis (Table 2). A higher 261 proportion of cases reported a history of gallstone disease than controls (19.2% vs. 13.3%) 262 but this did not reach the significance threshold (p=0.06). After adjustment for age, sex and 263 enrolment center at multivariable analysis, this latter association remained borderline 264 significant (OR 1.52, 95% CI 0.95-2.44, p=0.08) (Table 3). 265 
 266 
Non-diabetic medications 267 The use of proton pump inhibitors (PPI) (39.2% vs. 39.6%, p=0.97) and aspirin (22.5% vs. 268 26.5%, p=0.29) did not differ among cases and controls respectively (Table 2). 269 
 270 
Allergies 271 
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A history of allergies was not different in cases and in controls (28.9% vs. 25.0%, p=0.32). 272 Specifically, neither asthma (12.1% vs. 8.6%, p=0.19), eczema (11.1% vs. 7.6%, p=0.17) nor 273 hay fever (15.6% vs. 14.5%, p=0.79) were more prevalent in PNEN patients than in controls 274 (Table 2). 275  276 
Risk factors for the advanced grades and stages of PNEN  277 When stratifying cases for the TNM stage at diagnosis and for the tumor grade, diabetes 278 mellitus was statistically more prevalent in patients with G3 tumors (pancreatic neuro-279 endocrine carcinoma; PNEC) than with G1 or G2 tumors (40.9% vs. 15.8%, p=0.01). Amongst 280 cases, non-recent onset diabetes was associated with a more advanced stage at diagnosis 281 (TNM III-IV vs TNM I-II respectively 23.3% vs. 11.8%, p=0.05) and with a G3 vs G1-2 tumor 282 (respectively 40.9% vs. 14.9%, p=0.006). The use of metformin in combination with insulin 283 was more prevalent in patients with G3 than G1-G2 tumors (respectively 23.5% vs. 3.2%, 284 p=0.003) (Table 4). Asthma was more prevalent in G3 cases than in G1-2 (30.0% vs. 10.2% 285 p=0.02), and eczema was also more prevalent in G3 cases than in G1-2 but without reaching 286 statistical significance (25.0% vs. 9.6%, p=0.08). Coffee drinking was more prevalent in 287 localized disease (TNM 1-2) at diagnosis compared with advanced stage (TNM 3-4) (92.3% vs. 288 75.9%, p=0.003). 289  290   291 
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Discussion  292 The present study was designed to recruit cases of PNEN from multiple sites across Europe 293 using a standardised questionnaire in a face-to-face interview setting. To further strengthen 294 our method, we incorporated a preliminary power calculation based upon results from a 295 similar previous study. To the best of our knowledge, there have been six published studies to 296 have investigated risk factors for PNEN. Due to the low incidence of such tumors, which would 297 make a longitudinal cohort study highly problematic, it is not unexpected that these were all 298 case-control studies. Three were conducted in the USA, one in Europe and two in China (Ben 299 et al. 2016; Capurso et al. 2009; Halfdanarson et al. 2014; Hassan, et al. 2008a; Hassan et al. 300 2008b; Zhan et al. 2013).  Collective analysis of these studies has been limited by the variety   301 data collection methods employed, the selection of investigated exposures (and differing 302 definitions), in addition to the disparate population pools, all of which lead to substantial 303 heterogeneity (Haugvik et al. 2015). One study from China exclusively investigated a cohort of 304 insulinomas, with the exclusion of non-functioning endocrine tumors; the latter represent the 305 majority of PNEN cases, accounting from 60 to 90% of cases (Falconi et al. 2016). Another 306 study from China investigated a cohort of PNEN cases in which 63% had functioning tumors, 307 and 84% had early stage disease (Ben et al. 2016). The results of this study may have limited 308 applicability to other populations, as the majority of PNENs arising in Western populations 309 are non-functioning and would typically present with more advanced disease (Panzuto, et al. 310 2011). 311 The two publications from the USA reported different risk factors in the same population, 312 from a retrospective analysis of a large hospital database of neuroendocrine tumors (Hassan 313 et al. 2008a, b). None of the reported studies sought to investigate potentially protective 314 factors against the occurrence of PNENs. Two meta-analyses have summarized the results of 315 the previous primary studies and reached similar conclusions: Diabetes mellitus and family 316 
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history of cancer are risk factors for the occurrence of PNENs, whilst the role of 317 environmental factors was unclear and warranted further investigation (Haugvik et al. 2015; 318 Leoncini, et al. 2016). 319 Our study affirms an increased risk of PNEN occurrence with diabetes mellitus, 320 however it is noteworthy that we identify the significance of non-recent onset diabetes as a 321 risk factor. Four studies previously identified an association between PNEN and diabetes (Ben 322 et al. 2016; Capurso et al. 2009; Halfdanarson et al. 2014; Hassan et al. 2008b), however in 323 contrast to the current study, this association was for recent onset diabetes, which can 324 represent an epiphenomenon of the disease as suggested elsewhere for pancreatic 325 adenocarcinoma (Pannala, et al. 2008).  326 Given than beta cells typically express low levels of cytoprotective antioxidant 327 enzymes (Tiedge, et al. 1997), and because oxidative stress contributes to both the 328 pathogenesis of diabetes (Rolo and Palmeira 2006) and can potentiate somatic mutations, it 329 would not be unexpected for long standing diabetes to have an association with oncogenic 330 transformation of islet cells. Indeed, PNEN proliferation, tumor invasion and disease stage 331 have been found to be associated with expression of mTOR (mechanistic/mammalian target 332 of rapamycin) and its effectors (Capurso, et al. 2015), a cytoplasmic kinase that is activated by 333 both glucose and insulin (Blagosklonny 2013). 334 As the relation between diabetes and carcinogenesis is complex and still not clear, we sought 335 to specifically investigate the timing of onset of diabetes in respect to the clinical presentation 336 of the cancer. We therefore analyzed risk factors present at least 12 months before diagnosis, 337 minimizing the overlap between risk factors and cancer-related symptoms, which could 338 included cancer-induced endocrine insufficiency. With such premises, our results support the 339 view that long standing diabetes is a risk factor for PNEN rather than sign of disease. In order 340 to further analyze possible overlaps between diabetes as a risk factors and diabetes as a 341 
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cancer-related symptom, we performed a further sensitivity analysis, investigating several 342 different intervals of time between the onset of diabetes and the diagnosis of cancer.  Non 343 recent onset diabetes was confirmed to be increasingly consistent with the occurrence of 344 PNEN for intervals superior to 1 year and up to 5 years. For intervals of onset of diabetes 345 superior to 5 years this association was not anymore statistically significant. This might be 346 interpreted on the base of a lack of power of the study when considering small subgroups or,  347 alternatively, it could be biologically explained by the trophic influence that diabetes plays on 348 cancer. On the other hand one should also take into account that PNEN display a slower 349 growing rate compared to PDAC and therefore it might justify a major latency of occurrence of 350 symptom diabetes. 351 As the potential role of anti-diabetic drugs (metformin and insulin) in influencing pancreatic 352 carcinogenesis has been reported (De Souza, et al. 2016), we also specifically investigated the 353 role of such drugs in our multi-national cohort. Although the prevalent use insulin alone was 354 more frequent among cases than in controls (4.1% vs 1.6%), this difference was not significant 355 as the study was underpowered to assess it. 356 Another noteworthy finding of the present study was the increased proportion of 357 gallstone disease amongst PNEN cases compared to controls. However, this did not reach 358 statistical significance and we therefore cannot conclude that this was anything more than a 359 chance observation. The apparent proportional increase amongst cases, however, may reflect 360 the universal use of abdominal imaging in those diagnosed with PNEN, as compared to occult 361 gallstones in controls. It may be that our study was underpowered to detect a true association 362 between PNEN and biliary calculi, as the latter have been found to be associated with 363 
‘malignant neoplasm of the pancreas’ (ICD-Oncology C25.0-C25.9) as a single entity, using a 364 large combined US cancer registry with population-based controls (Nogueira, et al. 2014).  365 In the present study the rate of family history of cancer was not different between 366 
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cases and controls. This finding was in contrast with previous studies on this topic. However, 367 study design issues and/or selection bias in previous studies may account for this difference. 368 For example, three of these reports (Hassan et al. 2008a, b; Zhan et al. 2013) did not exclude 369 PNEN cases with genetic syndromes (ie. MEN1 or VHL). Of particular note, 25% of PNEN cases 370 had a genetic syndrome in the study by Zhan and colleagues, and therefore a higher 371 proportion of family history of any cancer would be expected (Zhan et al. 2013). Halfdanarson 372 and colleagues studied only sporadic cases, but excluded insulinomas and poorly differenced 373 PNECs which may have affected results in this regard (Halfdanarson et al. 2014). In the 374 present study, controls had a significantly higher number of siblings compared with cases, 375 potentially biasing the probability of cancer family history in the control study arm. On the 376 other hand, we found an association between 2nd degree family history of cancer and risk of 377 PNEN, thus suggesting that some kind of hereditary component might exist in this patients. 378 Environmental factors such as smoking and alcohol, even in high doses, did not 379 increase the risk of developing a PNEN in our study. This result is in keeping with the study by 380 Hassan and colleagues (Hassan et al. 2008b) but in contrast with others (Capurso 2009; 381 Halfdanarson et al. 2012; Zhan et al. 2013). A recent meta-analysis highlighted that the role of 382 smoking and alcohol might be less relevant in PNENs than in pancreatic adenocarcinoma 383 (Haugvik et al. 2015). To explore potential environmental factors which might alter the risk of 384 PNEN occurrence, we investigated for the first time a number of factors associated with a 385 lower incidence of pancreatic adenocarcinoma, such as the use of aspirin and a personal 386 history of allergies. No statistically significant differences were detected, possibly reflecting 387 intrinsic biological differences between endocrine and exocrine neoplasia of the pancreas. 388 Furthermore, as the power of the present study was based on risk factors for which there 389 were previous data, and this was not the case for previously uninvestigated exposures, a type 390 II error may have occurred. 391 
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Finally, we investigated the possible prognostic relevance of the investigated factors, 392 analyzing their distribution in PNEN patients according to their stage of disease at diagnosis 393 (TNM stages III or IV compared with I and II) or with their grade assessed by proliferative 394 activity (G1 and G2 compared to G3). Interestingly, of the prevalence of non-recent onset 395 diabetes was higher both in cases with metastatic disease (TNM stage III-IV) or advanced 396 grade (G3) at the time of diagnosis (Table 5). Drinking coffee was more frequent in cases with 397 localized disease at diagnosis. The use of metformin in combination with insulin, was also 398 associated with a more aggressive phenotype. Therefore, diabetes and use of insulin might 399 also exert a proliferative effect on tumor progression, as reported for other cancer types 400 (Vigneri, et al. 2016). 401 The present study displays several strengths as well as limitations. The strengths of the study 402 are represented by the relatively large sample size keeping in mind the low incidence of this 403 tumor type, the European multicentre setting (6 countries involved), the preliminary power 404 calculation, the investigation for the first time of a large set of factors possibly associated with 405 the risk of PNENs and the conduct of the study by face-to-face interview with a standardised 406 questionnaire. The inclusion criteria were clearly defined, controls were well matched for age 407 and gender with a 1:3 ratio and all questionnaires were administered by trained medical 408 doctors fluent in the local language, who evaluated exposures present 12 months before 409 diagnosis, to minimize bias due to cancer symptoms. Inherent with a multi-national case-410 control design, our study displays some limitations such as potential recall bias and 411 heterogeneity in data from different countries, although the analysis was corrected for centre 412 of enrollment. Furthermore, the analysis might have been underpowered for some of the 413 investigated factors and additional studies might be important to confirm the lack of 414 significant association. 415 Another important matter of concern, as for any case-control study, regards the choice of the 416 
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control population. We opted for a mixed control group that we believed to represent the 417 same population as the case group, as living in the same catchment area of the corresponding 418 cases, to limit possible bias that could have been specific of either hospital controls or visitors. 419 
Interestingly, “late onset diabetes” seemed to be associated with an increased risk of PNEN 420 with both kind of controls used in separate analyses. 421 In conclusion, the findings of this large multicentre case-control study suggest that 422 non-recent onset diabetes was associated with an increased risk of PNENs occurrence. Our 423 results do not support the view of a strict similarity with factors affecting the risk of 424 pancreatic adenocarcinoma. 425 
 426 
  427 
19 
 
19 
 
Declaration of interest 428 Potential competing interests: None. 429 Financial support: Gabriele Capurso was supported by AIRC grant IG 2015, Id 17177. 430 Guarantor of the article: Gabriele Capurso. 431 All authors approved the final version. 432 Specific author contributions: 433 Wrote the paper: Roberto Valente, Gabriele Capurso, Alastair Hayes. 434 Analyzed the data: Roberto Valente, Gabriele Capurso, Patrick Maisonneuve. 435 All authors contributed to the design, data collection, data interpretation, and writing of the 436 manuscript. 437 
 438 
Acknowledgements 439 
This study was conducted through Pancreas 2000, which is a European educational and scientific 440 
pancreatology programme initiated by the Karolinska Institutet in Stockholm, Sweden, and the 441 
European Pancreatic Club. 442 We also wish to acknowledge the contributions from the following sites: 443 
Italy: Dr Livia Archibugi, Dr Maria Rinzivillo. 444 
United Kingdom: Dr Lucy Wall, Dr Karen M Hayes, Mr Christos Skouras, Professor Rowan W 445 Parks, Professor Mark WJ Strachan [Edinburgh]; Mr Stuart M Robinson, Mr Colin H Wilson 446 [Newcastle]; Miss Tani Fasih, Mr Cho Ee Ng [Gateshead]. 447 
Norway: Prof. Ivar P. Gladhaug, Miss Kjerstin Skrede Mordal. 448 
Sweden: Dr Louise Bexander, Dr Isabel Sjöholm and Medical Student Anna Sjögren  449 
20 
 
20 
 
References 450 Ben Q, Zhong J, Fei J, Chen H, Yv L, Tan J & Yuan Y 2016 Risk Factors for Sporadic Pancreatic 451 Neuroendocrine Tumors: A Case-Control Study. Sci Rep 6 36073. 452 Capurso G, Archibugi L & Delle Fave G 2015 Molecular pathogenesis and targeted therapy of 453 sporadic pancreatic neuroendocrine tumors. J Hepatobiliary Pancreat Sci 22 594-601. 454 Capurso G, Falconi M, Panzuto F, Rinzivillo M, Boninsegna L, Bettini R, Corleto V, Borgia P, 455 Pederzoli P, Scarpa A, et al. 2009 Risk factors for sporadic pancreatic endocrine tumors: a 456 case-control study of prospectively evaluated patients. Am J Gastroenterol 104 3034-3041. 457 De Souza A, Khawaja KI, Masud F & Saif MW 2016 Metformin and pancreatic cancer: Is there a 458 role? Cancer Chemother Pharmacol 77 235-242. 459 Del Chiaro M, Verbeke C, Salvia R, Kloppel G, Werner J, McKay C, Friess H, Manfredi R, Van 460 Cutsem E, Lohr M, et al. 2013 European experts consensus statement on cystic tumours of the 461 pancreas. Dig Liver Dis 45 703-711. 462 Ellison TA, Wolfgang CL, Shi C, Cameron JL, Murakami P, Mun LJ, Singhi AD, Cornish TC, Olino 463 K, Meriden Z, et al. 2014 A single institution's 26-year experience with nonfunctional 464 pancreatic neuroendocrine tumors: a validation of current staging systems and a new 465 prognostic nomogram. Ann Surg 259 204-212. 466 Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, Kos-Kudla B, Kwekkeboom 467 D, Rindi G, Kloppel G, et al. 2016 ENETS Consensus Guidelines Update for the Management of 468 Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic 469 Neuroendocrine Tumors. Neuroendocrinology 103 153-171. 470 Fitzgerald TL, Hickner ZJ, Schmitz M & Kort EJ 2008 Changing incidence of pancreatic 471 neoplasms: a 16-year review of statewide tumor registry. Pancreas 37 134-138. 472 Gomez-Rubio P, Zock JP, Rava M, Marquez M, Sharp L, Hidalgo M, Carrato A, Ilzarbe L, 473 Michalski C, Molero X, et al. 2015 Reduced risk of pancreatic cancer associated with asthma 474 and nasal allergies. Gut. 475 Halfdanarson TR, Bamlet WR, McWilliams RR, Hobday TJ, Burch PA, Rabe KG & Petersen GM 476 2014 Risk factors for pancreatic neuroendocrine tumors: a clinic-based case-control study. 477 
Pancreas 43 1219-1222. 478 Hassan MM, Phan A, Li D, Dagohoy CG, Leary C & Yao JC 2008a Family history of cancer and 479 associated risk of developing neuroendocrine tumors: a case-control study. Cancer Epidemiol 480 
Biomarkers Prev 17 959-965. 481 Hassan MM, Phan A, Li D, Dagohoy CG, Leary C & Yao JC 2008b Risk factors associated with 482 neuroendocrine tumors: A U.S.-based case-control study. Int J Cancer 123 867-873. 483 Haugvik SP, Hedenstrom P, Korsaeth E, Valente R, Hayes A, Siuka D, Maisonneuve P, Gladhaug 484 IP, Lindkvist B & Capurso G 2015 Diabetes, smoking, alcohol use, and family history of cancer 485 as risk factors for pancreatic neuroendocrine tumors: a systematic review and meta-analysis. 486 
Neuroendocrinology 101 133-142. 487 Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, Scoazec JY, Salazar R, 488 Sauvanet A & Kianmanesh R 2012 ENETS Consensus Guidelines for the management of 489 patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor 490 syndromes. Neuroendocrinology 95 98-119. 491 Leoncini E, Carioli G, La Vecchia C, Boccia S & Rindi G 2016 Risk factors for neuroendocrine 492 neoplasms: a systematic review and meta-analysis. Ann Oncol 27 68-81. 493 Lepage C, Bouvier AM, Phelip JM, Hatem C, Vernet C & Faivre J 2004 Incidence and 494 management of malignant digestive endocrine tumours in a well defined French population. 495 
Gut 53 549-553. 496 Nogueira L, Freedman ND, Engels EA, Warren JL, Castro F & Koshiol J 2014 Gallstones, 497 cholecystectomy, and risk of digestive system cancers. Am J Epidemiol 179 731-739. 498 
21 
 
21 
 
Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM & Chari ST 2008 Prevalence and 499 clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 134 981-500 987. 501 Panzuto F, Boninsegna L, Fazio N, Campana D, Pia Brizzi M, Capurso G, Scarpa A, De Braud F, 502 Dogliotti L, Tomassetti P, et al. 2011 Metastatic and locally advanced pancreatic endocrine 503 carcinomas: analysis of factors associated with disease progression. J Clin Oncol 29 2372-504 2377. 505 Rindi G AR, Bosman F, Capella C, Klimstra D, Klöppel G, Komminoth P, Solcia E Nomenclature 506 and classification of neuroendocrine neoplasms of the digestive system. WHO Classification of 507 Tumours of the Digestive System. 508 Rolo AP & Palmeira CM 2006 Diabetes and mitochondrial function: role of hyperglycemia and 509 oxidative stress. Toxicol Appl Pharmacol 212 167-178. 510 Solcia E KpG, Sobin LH In collaboration with 9 pathologists from 4 countries 2002 World 511 Health Organization Histological Typing of Endocrine Tumors, 2nd edn. Berlin, Heidelberg, 512 New York. Sprinter Verlag pp. 1–5. 513 Streicher SA, Yu H, Lu L, Kidd MS & Risch HA 2014 Case-control study of aspirin use and risk 514 of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 23 1254-1263. 515 Tiedge M, Lortz S, Drinkgern J & Lenzen S 1997 Relation between antioxidant enzyme gene 516 expression and antioxidative defense status of insulin-producing cells. Diabetes 46 1733-517 1742. 518 Vigneri R, Goldfine ID & Frittitta L 2016 Insulin, insulin receptors, and cancer. J Endocrinol 519 
Invest 39 1365-1376. 520 Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, 521 Rashid A, et al. 2008 One hundred years after "carcinoid": epidemiology of and prognostic 522 factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26 3063-523 3072. 524 Zhan HX, Cong L, Zhao YP, Zhang TP & Chen G 2013 Risk factors for the occurrence of 525 insulinoma: a case-control study. Hepatobiliary Pancreat Dis Int 12 324-328. 526 
 527 
